Jun 15, 2020
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
Jun 09, 2020
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 08, 2020
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
May 26, 2020
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
May 21, 2020
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2020
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
Mar 06, 2020
Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
Feb 26, 2020
Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference
Dec 04, 2019
Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
Dec 04, 2019
Ardelyx Announces Proposed Public Offering of Common Stock
Dec 03, 2019
Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
Dec 02, 2019
Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
Nov 06, 2019
Ardelyx Announces Presentation at Kidney Week 2019
Nov 06, 2019
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
Oct 10, 2019
Ardelyx to Host Analyst Day in New York
Sep 17, 2019
Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
Sep 03, 2019
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Sep 02, 2019
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
Aug 09, 2019
Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
May 30, 2019
Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference